James C. Mullen

James C. Mullen both bought and sold Editas Medicine, Inc. stock: the purchase of March 2, 2021 (EUR 959,871) is the largest in the record, followed by May 18, 2018 (EUR 322,418); the two sales are dated October 18, 2021 (EUR 452,075) and January 3, 2022 (EUR 432,568). A third purchase, of EUR 144,604, dates from November 13, 2017 at Insulet Corp.

In all, 3 purchases for EUR 1.4 million (median EUR 322,418) and 2 sales for EUR 884,642. Purchases account for 60% of the market trades in the record.

The 21 filings, published between July 22, 2016 and May 22, 2025, are spread across Thermo Fisher Scientific Inc. (7, director), Editas Medicine (6, CEO), Patheon N.V. (5, Chief Executive Officer) and Insulet Corp (3, director). The record adds 13 share grants and 3 filings of another kind.

The pace peaks at 6 filings in 2017 and 5 in 2021. None falls in the last twelve months. Within 30 days of colleagues at Editas Medicine, Inc., Mullen has 2, 1 and 1 own market trades, in that order, all in the same direction. Names in order: Jessica Hopfield, Bruce Eaton and Lisa Anne Michaels.